HRP20230861T1 - PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA - Google Patents

PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA Download PDF

Info

Publication number: HRP20230861T1
Authority: HR; Croatia
Prior art keywords: n3pglu; antibody; patient; use according; brain
Prior art date: 2016-07-01

Application number

HRP20230861TT

Other languages

English (en)

Croatian (hr)

Inventor

Ronald Bradley Demattos

Michael Carl IRIZARRY

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-01

Filing date

2017-06-23

Publication date

2023-11-10

2017-06-23 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2023-11-10 Publication of HRP20230861T1 publication Critical patent/HRP20230861T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HRP20230861TT 2016-07-01 2017-06-23 PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA HRP20230861T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662357579P	2016-07-01	2016-07-01
PCT/US2017/038999 WO2018005282A1 (fr)	2016-07-01	2017-06-23	Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
EP17736841.2A EP3478712B1 (fr)	2016-07-01	2017-06-23	Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations

Publications (1)

Publication Number	Publication Date
HRP20230861T1 true HRP20230861T1 (hr)	2023-11-10

Family

ID=59295341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20230861TT HRP20230861T1 (hr)	2016-07-01	2017-06-23	PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA

Country Status (29)

Country	Link
US (2)	US11312763B2 (fr)
EP (2)	EP3478712B1 (fr)
JP (4)	JP7165588B2 (fr)
KR (3)	KR20210024213A (fr)
CN (3)	CN114917338A (fr)
AU (1)	AU2017291414B2 (fr)
BR (1)	BR112018073843A2 (fr)
CA (1)	CA3029550C (fr)
DK (1)	DK3478712T5 (fr)
EA (1)	EA201892690A1 (fr)
ES (1)	ES2958508T3 (fr)
FI (1)	FI3478712T3 (fr)
HR (1)	HRP20230861T1 (fr)
HU (1)	HUE062980T2 (fr)
IL (1)	IL263788B2 (fr)
LT (1)	LT3478712T (fr)
MA (1)	MA45543B1 (fr)
MD (1)	MD3478712T2 (fr)
MX (2)	MX2018016066A (fr)
NZ (1)	NZ772768A (fr)
PL (1)	PL3478712T3 (fr)
PT (1)	PT3478712T (fr)
RS (1)	RS64386B1 (fr)
SG (1)	SG11201810371XA (fr)
SI (1)	SI3478712T1 (fr)
TW (2)	TWI798751B (fr)
UA (2)	UA127101C2 (fr)
WO (1)	WO2018005282A1 (fr)
ZA (1)	ZA201807633B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI798751B (zh)	2016-07-01	2023-04-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
TWI789644B (zh)	2017-04-20	2023-01-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
EP3521308B1 (fr) *	2018-01-31	2024-03-13	Vivoryon Therapeutics N.V.	Anticorps humanisés et dé-immunisés
WO2019169448A1 (fr) *	2018-03-09	2019-09-12	St Vincent's Institute Of Medical Research	Anticorps multi-spécifiques
US20210324056A1 (en) *	2018-07-24	2021-10-21	Eisai R&D Management Co., Ltd.	Methods of treatment and prevention of alzheimer's disease
CN111184725B (zh) *	2020-02-27	2020-12-01	慈溪市人民医院医疗健康集团(慈溪市人民医院)	一种防治脑梗塞的药物制剂及其制备方法
TWI843040B (zh) *	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) *	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (fr)	2021-05-24	2022-12-01	Eli Lilly And Company	Anticorps anti-amyloïde bêta et leurs utilisations
EP4422751A1 (fr) *	2021-10-29	2024-09-04	Eli Lilly and Company	Composés et méthodes ciblant l'interleukine-34
KR20240105403A (ko) *	2021-10-29	2024-07-05	일라이 릴리 앤드 캄파니	인터류킨-34를 표적화하는 화합물 및 방법
CN118475610A (zh) *	2021-10-29	2024-08-09	伊莱利利公司	靶向白细胞介素-34的化合物和方法
MX2024005146A (es) *	2021-10-29	2024-05-13	Lilly Co Eli	Compuestos y metodos dirigidos a interleucina-34.
KR102753583B1 (ko) *	2021-11-11	2025-01-10	의료법인 명지의료재단	Kras 특이적 활성화 t 세포 유도용 항원 조성물
US20250099434A1 (en) *	2022-01-26	2025-03-27	T3D Therapeutics, Inc.	Methods of treating amyloid related brain disorders using novel compounds and antibodies
CA3243602A1 (fr) *	2022-02-03	2023-08-10	Eli Lilly And Company	Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer
WO2025106313A1 (fr)	2023-11-14	2025-05-22	Eli Lilly And Company	Dosages basés sur récepteur fc destinés à l'analyse d'anticorps igg

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1397539A (en) *	1920-01-14	1921-11-22	Odell Risdon Moore	Egg-carton
DE1257584T1 (de)	2000-02-24	2003-05-28	Lilly Co Eli	Humanisierte antikörper, die amyloid beta peptid demarkieren
US7122374B1 (en)	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (fr)	2002-07-24	2004-02-12	Innogenetics N.V.	Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide
EP1666061A1 (fr)	2003-09-09	2006-06-07	Takeda Pharmaceutical Company Limited	Utilisation d'un anticorps
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MY155286A (en)	2005-12-12	2015-09-30	Hoffmann La Roche	Antibodies against amyloid beta 4 with glycosylated in the variable region
RU2429244C2 (ru)	2006-03-23	2011-09-20	Байоарктик Ньюросайенс Аб	Улучшенные селективные в отношении протофибрилл антитела и их применение
EP2046833B9 (fr)	2006-07-14	2014-02-19	AC Immune S.A.	Anticorps humanisé contre l'amyloid beta
DK2121754T3 (en)	2007-01-18	2015-02-23	Lilly Co Eli	Pegylated amyloid BETA FAB
DK2182983T3 (da) *	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
CN102123726A (zh)	2008-06-12	2011-07-13	阿费里斯股份公司	用于治疗与帕金森氏病有关的症状的化合物
EP2321348A2 (fr)	2008-07-09	2011-05-18	University of Zürich	Procédé d'activation de la neurogenèse
WO2010009987A2 (fr)	2008-07-21	2010-01-28	Probiodrug Ag	Dosage d'anticorps de diagnostic
CN101397539B (zh) *	2008-10-14	2011-10-05	中国人民解放军第三军医大学	组织工程组织仿生培养的模拟人体生理应力的施力装置
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011151076A2 (fr)	2010-06-04	2011-12-08	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Anticorps monoclonaux ciblant des oligomères aβ
WO2012021475A2 (fr)	2010-08-12	2012-02-16	Eli Lilly And Company	ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
PL3042917T3 (pl) *	2010-08-12	2018-07-31	Eli Lilly And Company	Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US9499610B2 (en)	2011-04-08	2016-11-22	H. Lundbeck A/S	Antibodies specific to pyroglutamated Aβ
US20150315267A1 (en)	2012-12-07	2015-11-05	Thierry Bussiere	A method of reducing brain amyloid plaques using anti-ab antibodies
TWI593692B (zh)	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
EP3102230B1 (fr)	2014-02-08	2021-04-28	F. Hoffmann-La Roche AG	Méthode de traitement de la maladie d'alzheimer
WO2015175769A1 (fr) *	2014-05-15	2015-11-19	Biogen Ma Inc.	Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
WO2015191825A1 (fr)	2014-06-13	2015-12-17	Biogen Ma Inc.	Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
JP6201928B2 (ja) *	2014-08-04	2017-09-27	トヨタ自動車株式会社	車両制御装置
TWI570127B (zh)	2014-09-15	2017-02-11	美國禮來大藥廠	結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
US10017505B2 (en)	2014-09-30	2018-07-10	Merck Sharp & Dohme Corp.	Crystalline forms of a BACE inhibitor, compositions, and their use
MA41115A (fr) *	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
JOP20170004B1 (ar)	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh)	2016-07-01	2023-04-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途

2017
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active Ceased
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 NZ NZ772768A patent/NZ772768A/en unknown
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/fr active Active
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt active IP Right Grant
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/fr active Pending
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 DK DK17736841.2T patent/DK3478712T5/da active
- 2017-06-23 IL IL263788A patent/IL263788B2/en unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 UA UAA202202998A patent/UA129392C2/uk unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/fr not_active Ceased
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Withdrawn
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active Active
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 CA CA3029550A patent/CA3029550C/fr active Active
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
2020
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending

Also Published As

Publication number	Publication date
HUE062980T2 (hu)	2023-12-28
MA45543B1 (fr)	2023-08-31
KR20190012208A (ko)	2019-02-08
ZA201807633B (en)	2021-05-26
MD3478712T2 (ro)	2024-01-31
TW202140544A (zh)	2021-11-01
JP7165588B2 (ja)	2022-11-04
JP2023123503A (ja)	2023-09-05
ES2958508T3 (es)	2024-02-09
CN114917338A (zh)	2022-08-19
AU2017291414A1 (en)	2018-12-13
TW201811363A (zh)	2018-04-01
RS64386B1 (sr)	2023-08-31
US11312763B2 (en)	2022-04-26
TWI798751B (zh)	2023-04-11
US20190382471A1 (en)	2019-12-19
EA201892690A1 (ru)	2019-05-31
JP2019518783A (ja)	2019-07-04
DK3478712T3 (da)	2023-09-04
WO2018005282A1 (fr)	2018-01-04
JP7241058B2 (ja)	2023-03-16
CN109415433A (zh)	2019-03-01
JP2021059546A (ja)	2021-04-15
AU2017291414B2 (en)	2019-11-21
EP4272828A3 (fr)	2024-01-10
KR102221402B1 (ko)	2021-03-02
IL263788B2 (en)	2024-10-01
CN114887054A (zh)	2022-08-12
CA3029550A1 (fr)	2018-01-04
PT3478712T (pt)	2023-08-21
LT3478712T (lt)	2023-08-25
FI3478712T3 (fi)	2023-10-02
EP4272828A2 (fr)	2023-11-08
US20220235122A1 (en)	2022-07-28
KR20230021773A (ko)	2023-02-14
NZ772768A (en)	2024-11-29
MA45543A (fr)	2019-05-08
IL263788B1 (en)	2024-06-01
UA129392C2 (uk)	2025-04-09
JP2021059547A (ja)	2021-04-15
KR20210024213A (ko)	2021-03-04
DK3478712T5 (da)	2024-09-09
NZ748496A (en)	2021-02-26
EP3478712B1 (fr)	2023-07-19
TWI735600B (zh)	2021-08-11
EP3478712A1 (fr)	2019-05-08
CA3029550C (fr)	2023-08-22
MX2023001299A (es)	2023-02-22
PL3478712T3 (pl)	2023-11-06
BR112018073843A2 (pt)	2019-02-26
IL263788A (en)	2019-01-31
MX2018016066A (es)	2019-04-24
SI3478712T1 (sl)	2023-10-30
SG11201810371XA (en)	2018-12-28
UA127101C2 (uk)	2023-04-19

Publication	Publication Date	Title
HRP20230861T1 (hr)	2023-11-10	PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA
JP2015517572A5 (fr)	2015-10-15
HRP20130057T1 (hr)	2013-02-28	Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
MX394462B (es)	2025-03-11	ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS.
HRP20221263T1 (hr)	2023-03-03	Ciklički di-nukleotidni spojevi i postupci uporabe
WO2015191506A3 (fr)	2016-02-04	Pyrrolo[2,3-c]pyridines utilisables en tant qu'agents d'imagerie pour les enchevêtrements neurofibrillaires
WO2014178931A8 (fr)	2015-11-26	Utilisation de sobétirome dans le traitement de maladies ou de pathologies associées à la myélinisation
AR101177A1 (es)	2016-11-30	Inhibidores de la syk
CR20200246A (es)	2020-09-21	Compuestos y metodos para la reduccion de la expresion de snca
HRP20221158T1 (hr)	2022-12-09	Sredstva za izazivanje apoptoze
SI2849758T1 (en)	2018-07-31	Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
AR088458A1 (es)	2014-06-11	Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
HRP20210250T1 (hr)	2021-04-02	Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
MX385045B (es)	2025-03-14	Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer.
CR20200604A (es)	2021-02-09	Compuestos y métodos para reducir de la expresión de atxn3
PH12014502218A1 (en)	2015-01-12	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2015008777A (es)	2015-11-13	Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado.
HRP20191383T1 (hr)	2020-02-07	Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g
JP2017530130A5 (fr)	2018-11-01
WO2014160871A8 (fr)	2016-03-31	Procédés et agents pour le traitement de la maladie d'alzheimer
EP3003285A4 (fr)	2016-11-23	Forme dosifiée pharmaceutique solide de libération d'au moins un principe pharmaceutique actif dans la cavité buccale
HRP20210361T1 (hr)	2021-04-16	Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
SI3099307T1 (en)	2018-02-28	Use of cladribine for the treatment of neuromyelitis of the visual nerve
HRP20191030T1 (hr)	2019-09-06	Bumetanid za liječenje neurodegenerativnih bolesti s parkinsonovim sindromima
EP2966087A4 (fr)	2016-12-21	Anticorps dirigé contre un peptide codé par l'exon-21 de la périostine, et composition pharmaceutique pour la prévention ou le traitement d'une maladie inflammatoire contenant ledit anticorps